MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TERN had $4,732K increase in cash & cash equivalents over the period. -$19,773K in free cash flow.

Cash Flow Overview

Change in Cash
$4,732K
Free Cash flow
-$19,773K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-24,635 -48,001
Stock-based compensation expense
3,341 6,705
Depreciation expense
12 66
Net accretion on marketable securities
11 -135
Change in deferred taxes and uncertain tax positions
-34 -68
Amortization of right-of-use assets
99 211
Prepaid expenses and other current assets
1,153 -524
Accrued interest, net of interest received
-166 -207
Accounts payable
97 701
Accrued expenses and other liabilities
2,359 -3,452
Operating lease liabilities
-104 -214
Net cash used in operating activities
-19,773 -43,320
Purchase of property and equipment
0 0
Purchase of marketable securities
0 25,041
Proceeds from maturities of marketable securities
24,500 52,500
Net cash provided by investing activities
24,500 27,459
Net proceeds from the issuance of common stock and pre-funded warrants
0 -
Payment of deferred offering costs
0 6
Proceeds from stock option exercises
0 146
Proceeds from issuance of common stock under employee stock purchase plan
0 252
Net cash provided by financing activities
0 392
Effect of exchange rate changes on cash and cash equivalents
5 -4
Net (decrease) increase in cash and cash equivalents
4,732 -15,473
Cash and cash equivalents at beginning of period
161,439 -
Cash and cash equivalents at end of period
150,698 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Terns Pharmaceuticals, Inc. (TERN)

Terns Pharmaceuticals, Inc. (TERN)